U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C14H19N3O
Molecular Weight 245.3202
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXOLAMINE

SMILES

CCN(CC)CCC1=NC(=NO1)C2=CC=CC=C2

InChI

InChIKey=IDCHQQSVJAAUQQ-UHFFFAOYSA-N
InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C14H19N3O
Molecular Weight 245.3202
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Oxolamine under brand names Symphocal, Perebron is used in some countries as a cough suppressant for the treatment of pharyngitis, tracheitis, bronchitis, bronchiectasis, pertussis. Oxolamine possesses anti-inflammatory activity, which causes a reduction in the irritation of the nervous receptors of the respiratory tract.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Perebron

Approved Use

Unknown
Palliative
Perebron

Approved Use

Unknown
Palliative
Perebron

Approved Use

Unknown
Palliative
Perebron

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
15 mL single, oral
Overdose
Dose: 15 mL
Route: oral
Route: single
Dose: 15 mL
Sources:
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: M
Food Status: UNKNOWN
Sources:
Disc. AE: Visual hallucinations...
AEs leading to
discontinuation/dose reduction:
Visual hallucinations
Sources:
AEs

AEs

AESignificanceDosePopulation
Visual hallucinations Disc. AE
15 mL single, oral
Overdose
Dose: 15 mL
Route: oral
Route: single
Dose: 15 mL
Sources:
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: M
Food Status: UNKNOWN
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [IC50 6.3096 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
yes [IC50 5.0119 uM]
PubMed

PubMed

TitleDatePubMed
Effect of oxolamine on anticoagulant effect of warfarin.
2006 Jan 15
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats.
2007 Apr
Patents

Sample Use Guides

In general, 15-25 mg per kilogram per day should be given by dividing four equal doses. In children over 2 years: 1-2 ml of 5 ml Adults: 2 ml of 5 ml 4 times daily 4 hours a day, after an equal amount of water.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:46:24 GMT 2025
Edited
by admin
on Wed Apr 02 09:46:24 GMT 2025
Record UNII
90BEA145GY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OKSALAMIN
Preferred Name English
OXOLAMINE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
5-(2-(DIETHYLAMINO)ETHYL)-3-PHENYL-1,2,4-OXADIAZOLE
Systematic Name English
OXOLAMINE [MI]
Common Name English
SKF-9976 FREE BASE
Code English
Oxolamine [WHO-DD]
Common Name English
OXOLAMINE [MART.]
Common Name English
oxolamine [INN]
Common Name English
AF-438 FREE BASE
Code English
SKF 9976 FREE BASE
Code English
Classification Tree Code System Code
NCI_THESAURUS C257
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
WHO-VATC QR05DB07
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
WHO-ATC R05DB07
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
Code System Code Type Description
DRUG CENTRAL
2023
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
MESH
C008735
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
PUBCHEM
13738
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
RXCUI
32658
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m8313
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY Merck Index
INN
1453
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
WIKIPEDIA
Oxolamine
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
DRUG BANK
DB13216
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
ChEMBL
CHEMBL1620875
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
ECHA (EC/EINECS)
213-493-4
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
NCI_THESAURUS
C66274
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
CAS
959-14-8
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
EPA CompTox
DTXSID5023403
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
EVMPD
SUB09547MIG
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
SMS_ID
100000083052
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
FDA UNII
90BEA145GY
Created by admin on Wed Apr 02 09:46:24 GMT 2025 , Edited by admin on Wed Apr 02 09:46:24 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY